0617U CPT TruD MDS ASCVD Reimbursement

CPT code 0617U designates a Proprietary Laboratory Analyses (PLA) test — TruD MDS ASCVD from TruDiagnostic™ Inc. — that evaluates DNA methylation at over 20,000 sites in whole blood to provide a positive or negative risk classification for atherosclerotic cardiovascular disease. PLA codes are unique to a single manufacturer or laboratory and signal specialized molecular diagnostics entering clinical and payer consideration. Nationally, such tests are important for precision risk stratification and for payer coverage and coding policies that distinguish proprietary assays from broadly available tests.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of the test, the service and site-of-service context for billing, and how PLA designation affects coding practice. The publication summarizes benchmarks and policy considerations relevant to proprietary molecular assays, outlines typical payer coverage themes, and provides clinical context about the test’s intended role in assessing atherosclerotic cardiovascular disease risk.

Data not available in the input for specific modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and detailed service-line mapping.

Billing Code Overview

CPT code 0617U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the TruD MDS ASCVD test from TruDiagnostic™ Inc. The test analyzes DNA methylation at more than 20,000 sites in whole blood and uses an algorithmic analysis to report a positive or negative risk for atherosclerotic cardiovascular disease.

Service type: Proprietary laboratory molecular diagnostic assay (PLA)

Typical site of service: Clinical laboratory or reference laboratory; specimen collected in an outpatient or ambulatory setting

Data not available in the input for modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.

Clinical Context

A typical patient is a middle-aged adult with one or more cardiovascular risk factors (for example, hypertension, hyperlipidemia, smoking history, diabetes mellitus, or a family history of premature atherosclerotic cardiovascular disease). The clinician orders a proprietary molecular risk assay, TruD MDS ASCVD (0617U), to refine personalized risk stratification for atherosclerotic cardiovascular disease by analyzing DNA methylation patterns from a whole blood specimen. The clinical workflow: the patient is seen in an outpatient primary care, cardiology, or preventive medicine clinic; informed consent is obtained for a laboratory test; a phlebotomy draw of whole blood is performed (typical ambulatory laboratory or reference lab specimen collection); the sample is sent to the TruDiagnostic laboratory; the laboratory performs DNA methylation profiling across >20,000 CpG sites and runs the proprietary algorithm; results are returned to the ordering clinician as a binary positive/negative ASCVD risk report with interpretive comments; the clinician incorporates the result into shared decision-making regarding preventive therapies such as lifestyle modification, lipid management, or further diagnostic testing. Typical site of service is outpatient clinic with specimen collection at a physician office, outpatient laboratory, or drawing station; the testing is performed at the manufacturer’s designated reference laboratory.

Coding Specifications

Modifier	Description	When to Use
`26`

Taxonomy Code	Specialty	Notes
207Q00000X	Family Medicine	Primary care clinicians commonly order ASCVD risk stratification testing.
207R00000X	Internal Medicine	Internists order and interpret cardiovascular risk testing and manage preventive therapy.
207RC0000X	Cardiovascular Disease	Cardiology specialists may order the test for advanced risk assessment in complex patients.
2084P0800X	Preventive Medicine	Preventive medicine physicians and clinics focused on risk reduction order molecular risk assays.
363L00000X	Clinical Laboratory	Clinical laboratory personnel perform specimen handling and interface with the reference lab for testing logistics.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`I25.10`	Atherosclerotic heart disease of native coronary artery without angina pectoris	Indicates chronic atherosclerotic disease; relevant when using a methylation-based test to assess ASCVD risk or burden.
`I10`	Essential (primary) hypertension	Hypertension is a major ASCVD risk factor; commonly present in patients considered for advanced risk stratification.
`E78.5`	Hyperlipidemia, unspecified	Dyslipidemia is a primary driver of ASCVD risk; lipid disorders often prompt additional risk assessment.
`E11.9`	Type 2 diabetes mellitus without complications	Diabetes markedly increases ASCVD risk; clinicians use advanced risk markers to refine preventive strategies.
`Z13.6`	Encounter for screening for cardiovascular disorders	Screening context where clinicians may order molecular risk assays for personalized risk assessment.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80053`	Comprehensive metabolic panel	Often ordered concurrently to assess baseline metabolic status prior to cardiovascular risk management decisions.
`80061`	Lipid panel (cholesterol, HDL, LDL, triglycerides)	Standard laboratory evaluation for ASCVD risk assessment typically performed before or alongside advanced molecular testing.
`85025`	Complete blood count (CBC) with automated differential	Common baseline laboratory test obtained during outpatient evaluation; provides hematologic context for molecular assays.
`36415`	Collection of venous blood by venipuncture	The specimen collection procedure used to obtain whole blood for the `0617U` assay; billed by the entity performing phlebotomy when applicable.
`93000`	Electrocardiogram, routine ECG with interpretation and report	Noninvasive test often performed in cardiovascular risk evaluation and may be part of the same outpatient encounter.

OpenPayer

Summary & Overview

CPT 0617U: TruD MDS ASCVD DNA Methylation Cardiovascular Risk Test